A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines

A composition, neuropathic technology, applied in the field of pharmaceutical compositions for the treatment of acute, chronic pain and/or neuropathic pain and migraine, capable of solving problems such as dependence

Inactive Publication Date: 2004-01-14
PFIZER PRODS ETAT DE CONNECTICUT
View PDF40 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, despite the therapeutic use of analgesics to treat pain, there is still a significant bias toward the use of analgesic compounds
Specifically, many of these compounds that have been tested i

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] The present invention includes analgesics or pharmaceutically acceptable salts thereof for use in combination with NRPAs, such as opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCAs), Selective serotonin reuptake inhibitors (SSRIs), capsaicin receptor agonists, narcotics, benzodiazepines, skeletal muscle relaxants, migraine treatments, anticonvulsants, antihypertensives, antihypertensives Arrhythmic agents, antihistamines, steroids, caffeine, N-type calcium channel antagonists, and botulinum toxin. The references hereinafter collectively relate to quinuclidine, piperidine, ethylenediamine, pyrrolidine and azanorbornane derivatives that exhibit activity as substance P receptor antagonists and are useful in the pharmaceutical compositions and methods of the present invention And related compounds and their preparation methods: US Patent 5,162,339 published on November 11, 1992; US Patent 5,232,929 publi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Pharmaceutical compositions are disclosed for the treatment of acute, chronic and/or neuropathic pain. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anti-convulsants, anti-hypertensives, anti-arrythmics, antihistamines, steroids, caffeine, and botulinum toxin. The method of using these compounds and a method of treating acute, chronic and/or neuropathic pain and migraine in a mammal including a human is also disclosed.

Description

Background of the invention [0001] The present invention relates to a pharmaceutical composition for the treatment of acute, chronic and / or neuropathic pain and migraine in mammals, such as humans, comprising a nicotinic receptor partial agonist (NRPA) and an analgesic including the class Opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), capsaicin receptors Agonists, narcotics, benzodiazepines, skeletal muscle relaxants, migraine treatments, anticonvulsants, antihypertensives, antiarrhythmics, antihistamines, steroids, caffeine, N-type calcium channel antagonists and botulinum toxin. The term NRPA refers to all compounds that bind at neuronal nicotinic acetylcholine specific receptor sites in mammalian tissues and elicit a partial agonist response. A partial agonist response is defined herein as a partial or incomplete functional effect in a given functi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/00A61K31/4704A61K31/4748A61K31/5377A61K31/55A61K36/81A61K45/06A61P25/04A61P25/06A61P29/02A61P43/00
CPCA61K31/4748A61K31/4704A61K31/5377A61K45/06A61K31/55A61P25/02A61P25/04A61P25/06A61P29/00A61P29/02A61P43/00A61K2300/00
Inventor J·W·科E·P·哈里甘B·T·奥内尔S·B·桑兹E·J·瓦特斯基
Owner PFIZER PRODS ETAT DE CONNECTICUT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap